timothy sykes logo

Stock News

Pasithea Surprises: Will the Surge Continue?

Tim SykesAvatar
Written by Timothy Sykes Reviewed by Jack Kellogg Fact-checked by Ellis Hobbs
Updated 11/28/2025, 9:19 am ET 11/28/2025, 9:19 am ET | 5 min 5 min read
Pasithea Surprises: Will the Surge Continue? Thumbnail

Pasithea Therapeutics Corp.’s stocks have been trading up by 33.96 percent, driven by positive company developments.

Candlestick Chart

Live Update At 09:19:14 EST: On Friday, November 28, 2025 Pasithea Therapeutics Corp. stock [NASDAQ: KTTA] is trending up by 33.96%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Earnings and Financial Metrics Overview

As millionaire penny stock trader and teacher Tim Sykes, says, “There is always another play around the corner; don’t chase just because you feel FOMO.” In the ever-changing world of trading, it’s crucial to remain patient and not rush into decisions driven by the fear of missing out. Opportunities in the market are abundant, and approaching them with a level-headed mindset can often yield better results.

On looking over the financials of Pasithea Therapeutics Corp., a blend of optimism and caution emerges. Revenue dropped dramatically over the past three years, highlighting some deeper challenges they face. Yet, the significant increase in clinical achievements shows that science might be on KTTA’s side. Their financial strength showcases a high current ratio, representing an ability to cover short-term liabilities comfortably, shedding light on their resilient stance against financial turbulence.

However, their profitability ratios underline an urgent need for strategic intervention. Negative values in return on assets and equity suggest that while their groundbreaking cancer treatments are noteworthy, leveraging these into positive earnings remains a journey. Operating with minimal leverage, owing to zero long-term debt, it paves a path for unconventional strategies that could turn the financial picture around.

Their latest quarterly report provides insight into the struggles of balancing research costs with revenue generation, evidenced through significant net losses. There is clear focus and fervour around R&D, driving innovation but also representing financial challenges. Such high expenses point towards the company’s unyielding commitment to innovate in pursuit of breakthroughs, potentially shaping a winning formula eventually.

Trials and Triumphs of Pasithea’s PAS-004

Delving deeper, the large investment in PAS-004 is coming to bear fruit. Recent trial data reveals promising safety profiles while showcasing significant therapeutic benefits, providing much-needed hope to those grappling with advanced solid tumors. Recognition from the ALS Association is not just a financial milestone but also a trophy of potential acknowledgment for the path KTTA is journeying on.

More Breaking News

The opening of new trial sites, like at the University of Alabama, indicates a calculated expansion in research. This not only advances the treatment outreach but fortifies investor confidence with tangible achievements. The company’s outreach thereby goes beyond mere media mentions, affirming its standing as a proactive player in the therapeutic realm.

Potential Market Implications

These important leaps in treatment options have nudged KTTA stock into favorable investor limelight. With news descending favorably around PAS-004’s trials, the market responds with renewed interest in KTTA. Investors now eye the past year’s substantial decline not as discouragement but as potential grounds for opportunity with the company’s scientific progresses. Predicting a revival or long-term uplift remains nuanced; only the subduing of pressing profitability issues can seal the success.

The fluctuating stock prices stem from complex market calculations, blending hopeful clinical results with existing financial setbacks. The intraday fluctuations resonate around tangible stock value shifts, reflecting a volatile but dynamic engagement with the day’s breakthroughs. It’s vivid within the data – from low-priced stock buys leading to potential high-sell opportunities, all in response to rapid progress updates.

Conclusion: Poised for a Comeback?

In closing, Pasithea’s medical strides offer a beacon of recovery for its stock. The trading community is closely watching whether these scientific milestones will steer KTTA toward sustainable financial strength. While immediate gains may fuel transient excitement, the next pivotal step lies in translating clinical victories into sustained profitability. As millionaire penny stock trader and teacher Tim Sykes says, “The goal is not to win every trade but to protect your capital and keep moving forward.” This trading wisdom underscores the necessity of balancing risk management with aspirations for growth.

The journey of Pasithea is a tapestry of innovation entwined with financial reality, where hope meets strategy. For some, it stands as an emblem of potential rebirth and revitalized stock value. Meanwhile, for cautious onlookers, the narrative offers a gripping tale of risk juxtaposed with recovery potential. As the story unfolds, the future of KTTA may just hold further surprises waiting around the corner.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Tim Sykes

Head Writer at TimothySykes.com, Lead Mentor at the Trading Challenge
In his 20-plus years of trading, Tim has made $7.9 million. In his 15-plus years of teaching, Tim’s Trading Challenge has produced over 30 millionaire students. His philosophy emphasizes small gains and cutting losses quickly.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”